{"SPADE_N_03148": {"basic": {"SPADE ID": "SPADE_N_03148", "Peptide Name": "Neutrophil defensin 1 (Defensin, alpha 1; HNP-1, HP-1; Human, mammals, animals)", "Sequence": "ACYCRIPACIAGERRYGTCIYQGRLWAFCC", "Source": "Homo sapiens (Human)", "Biological Activity": ["Antimicrobial", "Antibacterial", "Anti-Gram+", "Anti-Gram-", "Antifungal", "Antiviral(SARS-CoV-2)"], "Target Organism": "[Ref.34206990]Virus:SARS-CoV-2:inhibition of infection in HEK293T-hACE2 cells(approximately 50% inbibition at 1 μg/mL (290 nM));SARS-CoV-2 variant P.1:inhibition of infection in HeLa-hACE2 cells(67% inbibition at 50 μg/mL);SARS-CoV-2 variant B.1.1.7:inhibition of infection in HeLa-hACE2 cells(58% inbibition at 50 μg/mL).[Ref.15616305] Gram-negative bacteria:Escherichia coli ATCC 8739 (vLD50=3.6±0.3 μg/ml), E. coli ATCC 25922 (vLD50=3.7±0.4 μg/ml), Enterobacter aerogenes ATCC 13048 (vLD50=10±0.5 μg/ml);Gram-positive bacteria:Staphylococcus aureus ATCC 25923 (vLD50=4.2±1.0 μg/ml), Staphylococcus aureus ATCC 29213 (vLD50=2.1±0.3 μg/ml), Bacillus cereus ATCC 10876 (vLD50=0.22±0.03 μg/ml).NOTE:vLD50, virtual lethal doses (vLDs), equivalent to conventional 50% lethal doses (LD50s).[Ref.15118082]Gram-positive bacteria:Bacillus subtilis (Inhibition zone=24 mm in PH5.5, Inhibition zone=20 mm in PH7.5 completely inhibit at 10 μg/well), Staphylococcus aureus  (Inhibition zone=1 mm in PH5.5, Inhibition zone=7 mm incompletely inhibit and Inhibition zone=2 mm completely inhibit in PH7.5 at 10 μg/well);Gram-negative bacteria:Escherichia coli (Inhibition zone=5 mm incompletely inhibit and Inhibition zone=2 mm completely inhibit in PH7.5 at 10 μg/well);Fungi:Candida albicans (Inhibition zone=13 mm in PH5.5, Inhibition zone=10 mm in PH7.5 completely inhibit at 10 μg/well).", "Linear/Cyclic": "Cyclic", "Sequence Length": 30}, "extended_data_url": "SPADE_N_03148_extended.json"}}